INTENSITY THERAPEUTICS INC (INTS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.10+2.50%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INTS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
INTS — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition. On August 11, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three and six months ended June 30, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by refer…
Why it matters: More capacity could help with funding and support growth efforts.
Supportive ifManagement says they have raised ATM capacity to $60M.
Worry ifThere is no news or delay in raising ATM offering capacity.
Why it matters: New funding is crucial for resuming full enrollment in the INVINCIBLE-3 Study. This could impact the company's growth prospects.
Supportive ifThe company will announce a new funding round or partnership for at least $5 million.
Worry ifNo new funding is secured. This leads to more delays in the INVINCIBLE-3 Study.
Why it matters: Good updates can boost the company's credibility. This could bring in more investment.
Supportive ifDetailed results show high pCR rates from the INVINCIBLE-4 Study.
Worry ifResults do not show major gains in effectiveness or safety.
Why it matters: Enrollment in France can help gather data and support the drug's claims.
Supportive ifPatient enrollment in the INVINCIBLE-4 Study starts in France.
Worry ifNo patient enrollment starts in France by the end of Q3 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$164 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $937 loss on $10,000 · 9.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,903 loss on $10,000 · 89.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Watching cash burn is important. It helps the company fund ongoing studies.
Worry ifCash burn stabilizes or decreases as new capital is raised.
Less concerning ifCash burn goes up even after raising new capital through the ATM facility.
Why it matters: Smaller operating losses show better financial health. This may improve how investors feel.
Supportive ifOperating losses decrease to less than $2 million for the next quarter.
Worry ifOperating losses go up or stay above $2.5 million. This shows financial problems.
Why it matters: Managing cash is crucial for funding ongoing studies. It shows if the company can sustain operations.
Worry ifCash and cash equivalents rise a lot from ATM raises.
Less concerning ifCash and cash equivalents decrease or remain stagnant despite ATM raises.
Why it matters: More money is needed to pay for ongoing studies. This affects the company's pipeline.
Supportive ifNew funding or partnerships will be announced to support clinical work.
Worry ifNo new capital raises or partnerships announced by the end of 2026.
Why it matters: Resuming enrollment is crucial for the Phase 3 trial's progress. It shows the company's commitment to advancing its cancer therapies.
Supportive ifEnrollment resumes in a limited number of U.S. sites by Q3 2026.
Worry ifNo enrollment resumes by the end of Q3 2026.
Why it matters: Updates on enrollment show progress in treating triple negative breast cancer. Good results can improve the company's image.
Supportive ifEnrollment in the INVINCIBLE-4 Study will be full by the end of 2027.
Worry ifEnrollment stalls or does not progress as planned.
Why it matters: Cash levels are critical for funding clinical trials. A drop could signal financial trouble.
Worry ifCash and cash equivalents remain above $8 million.
Less concerning ifCash and cash equivalents fall below $8 million.
Why it matters: New partnerships could provide funding and support for clinical trials. This would enhance the company's growth prospects.
Supportive ifLook for announcements of a new partnership with an investor or drug company.
Worry ifNo partnership announcements by the end of Q4 2026.